Completed PHASE2 INTERVENTIONAL NCT00196989

Study In People With Type 2 Diabetes

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus

Sponsor: GlaxoSmithKline

Conditions Diabetes Mellitus, Type 2

Interventions GW677954 Pioglitazone

Updated 8 times since 2017 Last updated: Mar 21, 2017 Started: Sep 30, 2005 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diabetes Mellitus, Type 2 and is currently completed. GlaxoSmithKline leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Albuquerque, United States , Alhambra, United States , Artesia, United States , Atlanta, United States , Auckland, New Zealand , Birmingham, United States , Bogotá, Colombia , Bonaventure, Canada , Box Hill, Australia and 113 more locations